Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS

2020198 citationsJournal Articlegreen Open Access

Authors

Michael Benatar · The University of Texas Health Science Center at San Antonio

Lanyu Zhang · The University of Texas Health Science Center at San Antonio

Lily Wang · The University of Texas Health Science Center at San Antonio

Volkan Granit · The University of Texas Health Science Center at San Antonio

Jeffrey Statland · The University of Texas Health Science Center at San Antonio

Richard J. Barohn · The University of Texas Health Science Center at San Antonio

Abstract

Serum NfL may be considered a clinically validated prognostic biomarker for ALS. Serum NfL (and perhaps pNfH), quantified using the Simoa assay, has potential utility as a pharmacodynamic biomarker of treatment effect.

Topics & Keywords

Amyotrophic Lateral Sclerosis Research Neurogenetic and Muscular Disorders Research

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Neurology

Volume 95, Issue 1, pp. e59-e69

DOI: 10.1212/wnl.0000000000009559

Field-Weighted Citation Impact: 10.61